Customize your JAMA Network experience by selecting one or more topics from the list below.
The era of precision medicine has arrived. A large share of new pharmaceuticals are tested and approved on the basis of biomarkers. Pharmacogenetics—the tailoring of drugs to patients based on 1 or more biomarkers—is used in conditions as diverse as HIV and thromboembolism.
Precision medicine raises hopes for patients and fears for those who try to ride herd on health care spending. Will patients finally live longer and healthier lives? Will society be able to afford it? Surprisingly, at this point, personalized medicine has had less effect on both health and medical spending than either its strongest backers hoped or its most apprehensive actuaries feared.
Cutler DM. Early Returns From the Era of Precision Medicine. JAMA. 2020;323(2):109–110. doi:10.1001/jama.2019.20659
Create a personal account or sign in to: